CA
NZ
UK
AU
IND
US
A gene therapy company focused on rare genetic disorders has received shareholder approval for its board of directors and auditor in a recent vote.
A biotech firm developing treatments for gout has announced a leadership change, appointing a co-CEO to guide its strategic direction.
The vote was documented in an SEC filing dated June 15, 2026, under accession number 0001493152-26-028699.
Clearmind Medicine Inc. (NASDAQ: CMND) is progressing through clinical trials for a potential treatment targeting alcohol use disorder (AUD). The company specializes in developing therapeutics aimed at addressing mental health conditions linked to alcohol consumption.
Coherus Oncology (NASDAQ: CHRS) has disclosed a notable change in its certifying accountant, a move that may influence investor perceptions and market sentiment. The announcement came via a Form 8-K filed with the SEC on June 12, 2026, detailing the firm’s transition in accounting …
Accendra Health Inc has announced a financing agreement with Regions Bank, reinforcing its financial structure. The arrangement outlines key obligations designed to support the company’s strategic objectives.
Belite Bio, Inc. (NASDAQ: BLTE) has achieved a key milestone by submitting a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Tinlarebant, a therapy targeting Stargardt Disease Type 1. This inherited retinal disorder remains a critical focus in ophthalmology …
A biotechnology firm disclosed its latest shareholder vote outcomes in a regulatory filing with the U.S. Securities and Exchange Commission. The company submitted a Form 8-K, detailing the results of its annual meeting. The document, assigned accession number **0001193125-26-271137**, confirmed the ratification of Ernst …
Dyadic Applied BioSolutions (NASDAQ: DYAI) is seeing heightened demand for its C1 microbial protein production platform as global health agencies prioritize rapid vaccine and antibody manufacturing amid the Bundibugyo Ebola virus outbreak.
A prominent oncology diagnostics company has initiated a $275 million private placement of convertible senior notes set to mature in 2032.
Please wait processing your request...